Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

  title={Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans},
  author={Simona Bramante and A. Koski and A. Kipar and I. Diaconu and Ilkka Liikanen and O. Hemminki and L. Vassilev and S. Parviainen and V. Cerullo and S. Pesonen and M. Oksanen and Raita Heiskanen and Noora Rouvinen-Lagerstr{\"o}m and Maiju Merisalo-Soikkeli and T. Hakonen and T. Joensuu and A. Kanerva and A. Hemminki},
  journal={International Journal of Cancer},
  • Simona Bramante, A. Koski, +16 authors A. Hemminki
  • Published 2014
  • Medicine
  • International Journal of Cancer
  • Sarcomas are a relatively rare cancer, but often incurable at the late metastatic stage. Oncolytic immunotherapy has gained attention over the past years, and a wide range of oncolytic viruses have been delivered via intratumoral injection with positive safety and promising efficacy data. Here, we report preclinical and clinical results from treatment of sarcoma with oncolytic adenovirus Ad5/3‐D24‐GMCSF (CGTG‐102). Ad5/3‐D24‐GMCSF is a serotype chimeric oncolytic adenovirus coding for human… CONTINUE READING
    32 Citations
    Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans
    • 30
    • PDF
    Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma
    • 36
    Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
    • 19
    Oncolytic viruses for cancer immunotherapy
    • 1
    Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
    • 24
    • PDF
    Review: Oncolytic Virotherapy, updates and future directions.
    • 71
    • PDF


    Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
    • 207
    Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
    • 174
    • PDF
    Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
    • 122
    • PDF
    Modified adenoviruses for cancer gene therapy
    • 136
    • PDF
    Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
    • 193
    • PDF
    Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors.
    • 155
    • PDF
    Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).
    • 131
    • PDF